ArticleInterdisciplinary sciences, computational life sciences2026
AMPred-MFG: Investigating the Mutagenicity of Compounds Using Motif-Based Graph Combined with Molecular Fingerprints and Graph Attention Mechanism.
Article in Interdisciplinary sciences, computational life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A benchmark dataset and interpretable deep learning framework for drug-induced developmental neurotoxicity prediction.RSC advances · 2026Article
- Article
- A unified multi-scale deep learning framework for molecular property prediction that bridges molecular structures and fingerprinting.Communications chemistry · 2026Article
- HopWD-DTA: a novel framework for drug-target affinity prediction fusing multi-hop neighborhoods and deep features.Journal of molecular modeling · 2026Article
- Cross-algorithm machine learning and consensus features for early disseminated intravascular coagulation risk prediction in sepsis-induced coagulopathy.Journal of translational medicine · 2026Article
- ARID3A Dysregulation Drives Colon Cancer Progression and Enhances Responsiveness to Aspirin.Journal of cellular and molecular medicine · 2026Article
- ADFC-ATP: Attention-Guided Dual-View Fusion and Contrastive Pretraining for Robust Aquatic Toxicity Prediction.Journal of cellular and molecular medicine · 2026Article
- E-SegNet: E-Shaped Structure Networks for Accurate 2D and 3D Medical Image Segmentation.Research (Washington, D.C.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Accurate mutagenicity prediction is crucial in drug discovery, but evaluating the mutagenicity of drug molecules is technically challenging, and experimental mutagenicity tests are both time-consuming and costly. In this study, we introduce a new deep learning predictive model called AMPred-MFG, designed to predict the mutagenicity of drug molecules. Our approach first combines multiple molecular fingerprint features with molecular graph features to obtain a comprehensive molecular representation. Next, considering the significance of molecular substructures on mutagenicity, we decompose the molecules into motifs to form motif-based graph. We use a graph transformer to extract features from these motif-based graphs and fuse motif graph features with molecular fingerprint features and molecular graph features to create the final molecular representation. Finally, we use a multilayer perceptron to classify the compounds into mutagens and non-mutagens. We evaluate the performance of AMPred-MFG through ten-fold cross-validation experiments and validate its robustness on external validation datasets. By comparing with several state-of-the-art algorithms, AMPred-MFG achieves the best results in terms of performance, with AUC value of 0.912, ACC of 0.835, SEN of 0.849, NPV of 0.811, PPV of 0.854, MCC of 0.665. In addition, we use attention scores to identify molecular fragments related to mutagenicity, highlighting the interpretability of AMPred-MFG. We believe that AMPred-MFG can act as a dependable tool for predicting mutagenicity, allowing for the assessment of both mutagens and non-mutagens during the early phases of drug development. AMPred-MFG is freely available at https://github.com/zhaoqi106/AMPred-MFG .
Indexed as
Identifiers
40670804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.